Abbvie has been falling hard on news that it will sell off some drug patents in order to win approval for its merger with Allergan. It is entering a support zone between about $77 and $81, however, and it may start to climb from here as investors start to get excited about the merger. Also look for Coronavirus news to move the stock; word on the street is that one of Abbvie's drugs is being used off-label to treat Coronavirus patients.
With a 5.67% dividend yield and a forward P/E under 10, ABBV looks attractively valued. True, the patent sales will probably negatively affect that forward P/E, and the merger might ultimately result in a lower dividend yield. But Abbvie will also pocket a bunch of cash from those drug sales that can be used to grow its pipeline, and Allergan's forward P/E is also low, with plenty of potential upside.
With a 5.67% dividend yield and a forward P/E under 10, ABBV looks attractively valued. True, the patent sales will probably negatively affect that forward P/E, and the merger might ultimately result in a lower dividend yield. But Abbvie will also pocket a bunch of cash from those drug sales that can be used to grow its pipeline, and Allergan's forward P/E is also low, with plenty of potential upside.
